IMPACT OF UPADACITINIB OR ADALIMUMAB AS INITIAL THERAPY ON THE ACHIEVEMENT OF 48-WEEK TREATMENT GOALS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE: POST HOC ANALYSIS OF A PHASE 3 STUDY

被引：1
|
作者：
Mysler, E. [1 ]
Tanaka, Y. [2 ]
Kavanaugh, A. [3 ]
Aletaha, D. [4 ]
Taylor, P. C. [5 ]
Song, I. H. [6 ]
Shaw, T. [6 ]
Song, Y. [6 ]
Demasi, R. [6 ]
Ali, M. [6 ]
Fleischmann, R. [7 ]
机构：
[1] Org Med Invest, Rheumatol, Buenos Aires, DF, Argentina
[2] Univ Occupat & Environm Hlth, Dept Internal Med 1, Kitakyushu, Fukuoka, Japan
[3] Univ Calif San Diego, Sch Med, Div Rheumatol Allergy & Immunol, San Diego, CA 92103 USA
[4] Med Univ Vienna, Dept Med 3, Div Rheumatol, Vienna, Austria
[5] Univ Oxford, Botnar Res Ctr, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England
[6] AbbVie Inc, Rheumatol, N Chicago, IL USA
[7] Univ Texas Southwestern Med Ctr Dallas, Metroplex Clin Res Ctr, Dept Med, Dallas, TX 75390 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2021年 / 80卷
关键词：
D O I：
10.1136/annrheumdis-2021-eular.474
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
POS0653
引用
收藏
页码：566 / 567
页数：2
相关论文
共 50 条
  • [1] Impact of Upadacitinib or Adalimumab as Initial Therapy on the Achievement of 48-Week Treatment Goals in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate: Post Hoc Analysis of a Phase 3 Study
    Mysler, Eduardo
    Tanaka, Yoshiya
    Kavanaugh, Arthur
    Aletaha, Daniel
    Taylor, Peter
    Song, In-Ho
    Shaw, Tim
    Song, Yanna
    DeMasi, Ryan
    Ali, Mira
    Fleischmann, Roy
    [J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [2] Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE
    Mysler, Eduardo
    Tanaka, Yoshiya
    Kavanaugh, Arthur
    Aletaha, Daniel
    Taylor, Peter C.
    Song, In-Ho
    Shaw, Tim
    Song, Yanna
    DeMasi, Ryan
    Ali, Mira
    Fleischmann, Roy
    [J]. RHEUMATOLOGY, 2023, 62 (05) : 1804 - 1813
  • [3] Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study)
    Koike T.
    Harigai M.
    Ishiguro N.
    Inokuma S.
    Takei S.
    Takeuchi T.
    Yamanaka H.
    Takasaki Y.
    Mimori T.
    Hiramatsu K.
    Komatsu S.
    Tanaka Y.
    [J]. Rheumatology and Therapy, 2016, 3 (1) : 129 - 141
  • [4] A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib to Placebo and to Adalimumab, in Patients with Active Rheumatoid Arthritis with Inadequate Response to Methotrexate
    Fleischmann, Roy
    Pangan, Aileen L.
    Mysler, Eduardo
    Bessette, Louis
    Peterfy, Charles
    Durez, Patrick
    Ostor, Andrew
    Li, Yihan
    Zhou, Yijie
    Othman, Ahmed A.
    Song, In-Ho
    Genovese, Mark C.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [5] Patient-Reported Outcomes of Upadacitinib versus Adalimumab Use in Patients with Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate: 26-Week Analysis of a Phase 3 Study
    Fleischmann, Roy
    Bergman, Martin
    Tundia, Namita
    Song, In-Ho
    Suboticki, Jessica
    Song, Yan
    Strand, Vibeke
    [J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [6] PREDICTIVE FACTORS FOR REMISSION ACHIEVEMENT BY TOCILIZUMAB MONOTHERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS AFTER INADEQUATE RESPONSE TO METHOTREXATE: A POST HOC ANALYSIS OF THE SURPRISE STUDY
    Kato, Masaru
    Kaneko, Yuko
    Tanaka, Yoshiya
    Inoo, Masayuki
    Kobayashi-Haraoka, Hitomi
    Amano, Koichi
    Miyata, Masayuki
    Murakawa, Yohko
    Yasuoka, Hidekata
    Hirata, Shintaro
    Nagasawa, Hayato
    Tanaka, Eiichi
    Miyasaka, Nobuyuki
    Yamanaka, Hisashi
    Yamamoto, Kazuhiko
    Yokota, Isao
    Atsumi, Tatsuya
    Takeuchi, Tsutomu
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 714 - 715
  • [7] Baricitinib versus placebo or adalimumab in patients with active rheumatoid arthritis and an inadequate response to background methotrexate therapy: Results of a phase 3 study
    Taylor, P. C.
    Keystone, E. C.
    van der Heijde, D.
    Tanaka, Y.
    Ishii, T.
    Emoto, K.
    Yang, L.
    Arora, V
    Gaich, C.
    Rooney, T.
    Schlichting, D.
    Macias, W. L.
    de Bono, S.
    Weinblatt, M. E.
    [J]. SWISS MEDICAL WEEKLY, 2016, 146 : 9S - 9S
  • [8] Baricitinib Versus Placebo or Adalimumab in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to Background Methotrexate Therapy: Results of a Phase 3 Study
    Taylor, Peter C.
    Keystone, Edward C.
    van der Heijde, D.
    Tanaka, Yoshiya
    Ishii, Taeko
    Emoto, Kahaku
    Yang, Lili
    Arora, Vipin
    Gaich, Carol L.
    Rooney, Terence
    Schlichting, Douglas E.
    Macias, William
    de Bono, Stephanie
    Weinblatt, Michael E.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [9] Baricitinib vs. placebo or adalimumab in patients with active rheumatoid arthritis and an inadequate response to background methotrexate therapy: results of a phase 3 study
    Taylor, P.
    Keystone, E. C.
    van der Heijde, D.
    Tanaka, Y.
    Ishii, T.
    Emoto, K.
    Yang, L.
    Arora, V.
    Gaich, C.
    Rooney, T.
    Schlichting, D.
    Macias, W. L.
    De Bono, S.
    Weinblatt, M. E.
    Larsson, E.
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2016, 45 : 8 - 8
  • [10] Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response
    Fleischmann, Roy M.
    Genovese, Mark C.
    Enejosa, Jeffrey V.
    Mysler, Eduardo
    Bessette, Louis
    Peterfy, Charles
    Durez, Patrick
    Ostor, Andrew
    Li, Yihan
    Song, In-Ho
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 (11) : 1454 - 1462
12345